These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 16772765)

  • 1. Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase enzyme activity: a randomized, controlled trial.
    Alper AB; Tomlin H; Sadhwani U; Whelton A; Puschett J
    Am J Ther; 2006; 13(3):229-35. PubMed ID: 16772765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II.
    Knudsen JF; Carlsson U; Hammarström P; Sokol GH; Cantilena LR
    Inflammation; 2004 Oct; 28(5):285-90. PubMed ID: 16134002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
    Weber A; Casini A; Heine A; Kuhn D; Supuran CT; Scozzafava A; Klebe G
    J Med Chem; 2004 Jan; 47(3):550-7. PubMed ID: 14736236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
    Schwartz JI; Vandormael K; Malice MP; Kalyani RN; Lasseter KC; Holmes GB; Gertz BJ; Gottesdiener KM; Laurenzi M; Redfern KJ; Brune K
    Clin Pharmacol Ther; 2002 Jul; 72(1):50-61. PubMed ID: 12152004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
    Di Fiore A; Pedone C; D'Ambrosio K; Scozzafava A; De Simone G; Supuran CT
    Bioorg Med Chem Lett; 2006 Jan; 16(2):437-42. PubMed ID: 16290146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
    White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
    Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of adjuvant-induced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II.
    Katagiri M; Ogasawara T; Hoshi K; Chikazu D; Kimoto A; Noguchi M; Sasamata M; Harada S; Akama H; Tazaki H; Chung UI; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2006 Feb; 21(2):219-27. PubMed ID: 16418777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of carbonic anhydrase by parathyroid hormone and cyclic AMP in rat renal cortex in vitro.
    Beck N; Kim KS; Wolak M; Davis BB
    J Clin Invest; 1975 Jan; 55(1):149-56. PubMed ID: 233968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.
    Rossat J; Maillard M; Nussberger J; Brunner HR; Burnier M
    Clin Pharmacol Ther; 1999 Jul; 66(1):76-84. PubMed ID: 10430112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action.
    Puscas I; Ifrim M; Maghiar T; Coltau M; Domuta G; Baican M; Hecht A
    Int J Clin Pharmacol Ther; 2001 Jun; 39(6):265-70. PubMed ID: 11430635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells.
    Anai S; Tanaka M; Shiverick KT; Kim W; Takada S; Boehlein S; Goodison S; Mizokami A; Rosser CJ
    J Urol; 2007 May; 177(5):1913-7. PubMed ID: 17437847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM; Reeves MJ; Whelton A
    Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
    Daniels S; Robbins J; West CR; Nemeth MA
    Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials.
    Soni P; Shell B; Cawkwell G; Li C; Ma H
    Curr Med Res Opin; 2009 Aug; 25(8):1841-51. PubMed ID: 19530981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The vasodilating effect of acetazolamide and dorzolamide involves mechanisms other than carbonic anhydrase inhibition.
    Torring MS; Holmgaard K; Hessellund A; Aalkjaer C; Bek T
    Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):345-51. PubMed ID: 18757514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of acetazolamide and carbonic anhydrase inhibition on erythrocyte 2,3-diphosphoglycerate content and metabolism.
    Rolf LL; Garg LC
    J Pharmacol Exp Ther; 1975 May; 193(2):639-46. PubMed ID: 1142109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbonic anhydrase inhibitors that directly inhibit anion transport by the human Cl-/HCO3- exchanger, AE1.
    Morgan PE; Supuran CT; Casey JR
    Mol Membr Biol; 2004; 21(6):423-33. PubMed ID: 15764372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of selective cyclooxygenase-2 inhibitors.
    Krum H; Liew D; Aw J; Haas S
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):265-70. PubMed ID: 15151474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation.
    Knight S; Johns EJ
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):11-6. PubMed ID: 18047621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
    Sieper J; Klopsch T; Richter M; Kapelle A; Rudwaleit M; Schwank S; Regourd E; May M
    Ann Rheum Dis; 2008 Mar; 67(3):323-9. PubMed ID: 17616556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.